ALPANSEAlpa Laboratories Limited· PharmaceuticalsHighNeutral
Announced Fri, 29 May · 22:40 IST

Alpa Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Revenue DeclineResults View source PDF

ALPA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.6%1-day move
₹71.44
prior close
₹72.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.4-0.8-1.8-3.4-0.6-3.4-3.8-3.3-4.5-4.8-5.0-4.1
Up moveDown movePending
AI summary

Alpa Laboratories Limited reported standalone revenue from operations of ₹10,580.96 lakhs for FY26, down from ₹11,164.49 lakhs in FY25, marking a ~5.2% decline. Profit After Tax (PAT) stood at ₹1,495.31 lakhs versus ₹1,967.94 lakhs in the prior year, a decline of ~24% YoY. PBT fell to ₹1,664.05 lakhs from ₹2,584.12 lakhs. The company maintained a clean audit with an unmodified opinion from C.H. Padliya & Co. Operating cash flow was ₹995.04 lakhs, while investing outflows of ₹1,158.08 lakhs (including capex and investments) exceeded operating inflows. The board also appointed new internal and cost auditors for FY27.

Likely market impact

The ~24% decline in PAT and ~5% revenue decline indicate pressure on profitability, though the company retains positive operating cash flow. Shareholders should monitor revenue recovery in FY27 given the back-to-back earnings decline.